Literature DB >> 21467600

Teratogenic determinants of first-trimester exposure to antiepileptic medications.

Koby Brosh1, Ilan Matok, Eyal Sheiner, Gideon Koren, Arnon Wiznitzer, Rafael Gorodischer, Amalia Levy.   

Abstract

OBJECTIVE: To investigate the potential impact of exposure to anti epileptic medications during the first-trimester of pregnancy on major malformations. STUDY
DESIGN: A retrospective cohort study comparing all pregnancies of women with and without exposure to antiepileptic medications during pregnancy was performed. A computerized database of medications dispensed from 1998 to 2008 to all women registered in the "Clalit" health maintenance organization, was linked with computerized and non computerized databases containing maternal and infant hospitalization records from the district hospital. Exposed women were further analyzed by mono and poly- antiepileptic therapy during pregnancy. Stratified analyses, using multiple logistic regression models were performed to control for confounders.
RESULTS: During the study period 99,724 deliveries and 1012 pregnancy terminations occurred; of those, 421 (0.42%) were exposed to one or more antiepileptic medications during the first trimester. A higher rate of major congenital malformations was detected among women who were exposed, as compared to those unexposed to antiepileptic medications during the first-trimester (10.0% vs. 7.0%; P=0.02). The association remained significant after adjusting for maternal age, ethnicity, smoking, diabetes and parity (adjusted OR= 1.50; 95% CI 1.06-2.12; p=0.02). Specifically, the risk was significant for antiepileptic anti folate drugs (n=210; adjusted OR= 1.95; 95% CI 1.25-3.03; P=0.003). Poly-antiepileptic therapy was significantly associated with major congenital malformations (26.5% vs. 5.7%, P<0.001). Using a multiple logistic regression model, controlling for ethnicity, diabetes, smoking, maternal age and parity, poly-antiepileptic therapy was an independent risk factor for major congenital malformations (adjusted OR= 7.98; 95% CI 3.4-18.7; P<0.001), while mono-therapy lost its independent association with major congenital malformations (adjusted OR= 1.23; 95% CI 0.8-1.8; P=0.28).
CONCLUSION: First-trimester exposure to antiepileptic medications is an independent risk factor for major congenital malformations. The risk is significantly higher for anti folate antiepileptic drugs and for poly-antiepileptic therapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21467600

Source DB:  PubMed          Journal:  J Popul Ther Clin Pharmacol        ISSN: 2561-8741


  5 in total

Review 1.  Neonatal Adaptation Issues After Maternal Exposure to Prescription Drugs: Withdrawal Syndromes and Residual Pharmacological Effects.

Authors:  Irma Convertino; Alice Capogrosso Sansone; Alessandra Marino; Maria T Galiulo; Stefania Mantarro; Luca Antonioli; Matteo Fornai; Corrado Blandizzi; Marco Tuccori
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

2.  Anti-epileptic drug exposure during pregnancy and neonatal birth weight outcomes: protocol for a systematic review and meta-analysis.

Authors:  Alekhya Lavu; Christine Vaccaro; Walid Shouman; Silvia Alessi Severini; Sherif Eltonsy
Journal:  Syst Rev       Date:  2021-05-29

3.  Evaluation of Hematological Parameters in the Genetic Prospective in Epileptic Patients of Khyber Pakhtunkhwa.

Authors:  Nazish Farooq; Niaz Ali; Shakir Ullah
Journal:  Pharmgenomics Pers Med       Date:  2019-12-23

4.  The course and outcome of pregnancy and neonatal situation in epileptic women.

Authors:  Mohammad Reza Najafi; Farnoosh Sonbolestan; Seyed Ali Sonbolestan; Mohammad Zare; Jafar Mehvari; Shahrokh Noori Meshkati
Journal:  Adv Biomed Res       Date:  2012-03-28

5.  Pharmacogenetic evaluation of ABCB1, Cyp2C9, Cyp2C19 and methylene tetrahydrofolate reductase polymorphisms in teratogenicity of anti-epileptic drugs in women with epilepsy.

Authors:  Manna Jose; Moinak Banerjee; Anila Mathew; Tashi Bharadwaj; Neetha Vijayan; Sanjeev V Thomas
Journal:  Ann Indian Acad Neurol       Date:  2014-07       Impact factor: 1.383

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.